Forest to buy $350M in shares from Morgan Stanley; Abbott targeted in two Depakote liability suits;

@FiercePharma: Pfizer wins Viagra patent case against Teva. Court says drug protected from competition until 2019. Story | Follow @FiercePharma

> Forest Laboratories has agreed to repurchase $350 million in common stock from Morgan Stanley, about 3.2% of the company's market value. News

> Abbott Laboratories was targeted in two Illinois lawsuits that allege its seizure drug Depakote caused birth defects. Item

> Americans with heart failure may benefit less from beta blocker drugs than people from other countries, a new meta-analysis suggests. Article

> U.K. officials met with GlaxoSmithKline representatives in ongoing talks about the company's choice of a site for a new manufacturing center. Story

> Fevers caused by mild cases of swine flu may respond as well to a Chinese herbal therapy as they do to Roche's Tamiflu drug. Report

> Contract manufacturing is expected to return to previous growth levels over the next 5 years after a tough 2009 and 2010. Piece

Biotech News

@FierceBiotech: China: The next biotech superpower? Piece | Follow @FierceBiotech

@JohnCFierce: Shanghai Pharma looking for a mid-sized U.S. or European pharma buy. Reuters: News| Follow @JohnCFierce

@RyanMFierce: DREAM team finding best algorithms for inferring biological networks more complex than originally thought. Item | Follow @RyanMFierce

@MaureenFierce: MIT's Lincoln Lab researchers have developed tech that may someday cure the any virus. Story | Follow @MaureenFierce

> Gilead hunts for deals as it pursues combo cancer drug quest. Story

> Cancer drug developers rattled by widespread shortages. News

> Report: Carlyle Group talks to buy PPD for about $4B. More

Biotech Research News

> An optogenetic pacemaker would march to a fiber-optic beat. Details

> Genes reveal gender differences in alcoholism onset. Article

> Stanford researchers separate tumor-causing cells from therapeutic ones. News

> Researchers reach for broader firepower against viruses. More

> Jackson Lab off the hook in Alzheimer's mice lawsuit. Report

> Heart regeneration, or finding our own inner zebrafish. Story

Manufacturing News

> Avastin fakes in China were not contaminated, investigation continues. More

> Harbin faces Chinese regulators for environmental violations. Article

> State incentives help hook Watson, Osmotica. News

> Generics deal sounds alarm for foreign API makers. Story

> "Expendable" mid-managers are last defense for quality. Details

> Gilead clears GMP violations amid HIV drug approval. Report

And Finally... Exercise 15 minutes a day, add three years to your life. More

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.